Physician profile
A Matthew Brunner
NPI 1811993223
$1,033,101.13
in general payments reported to CMS, 2019-2025
33 companies · $353K in 2025
The $353K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120K · 2022: $161K · 2023: $142K · 2024: $258K · 2025: $353K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $361K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $136K · Consulting Fee: $103K · Travel and Lodging: $56K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $42K · Honoraria: $23K · Food and Beverage: $21K · Education: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $361,400.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $135,552.75 |
| Consulting Fee | $103,333.23 |
| Travel and Lodging | $56,186.02 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $41,700.00 |
| Honoraria | $22,500.00 |
| Food and Beverage | $20,648.61 |
| Education | $11,433.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $506,699.00 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $210,434.92 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Janssen Biotech, INC. | $72,812.67 | 2021-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61,199.53 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Leo Pharma INC. | $48,362.31 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| E.R. Squibb & Sons, L.L.C. | $21,212.09 | 2021-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $19,087.55 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $16,346.44 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15,017.27 | 2022-2025 | Spevigo |
| Dermavant Sciences, INC. | $12,970.32 | 2023-2024 | Vtama, Tapinarof |
| Arcutis Biotherapeutics, INC. | $10,970.99 | 2023-2025 | Zoryve |
| Incyte Corporation | $10,846.28 | 2021-2025 | Opzelura |
| Genzyme Corporation | $8,730.42 | 2021-2025 | |
| Pfizer INC. | $6,084.90 | 2021-2023 | |
| Ucb, INC. | $4,878.01 | 2021-2025 | Bimzelx, Cimzia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $2,108.06 | 2023-2024 | Olumiant, Ebglyss |
| Organon LLC | $1,735.52 | 2025 | Vtama |
| Amgen INC. | $1,169.24 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $596.85 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $584.40 | 2021-2024 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $325.04 | 2021-2025 | Nemluvio, Aklief |
| Sanofi-Aventis U.S. LLC | $144.70 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $139.88 | 2023-2024 | Ycanth |
| Almirall LLC | $108.02 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.31 | 2025 | Siliq |
| Vyne Pharmaceuticals INC. | $93.65 | 2021 | |
| Bausch Health US, LLC | $65.92 | 2021 | |
| Mayne Pharma Commercial LLC | $62.01 | 2022-2024 | |
| Epi Health, LLC | $53.95 | 2021 | |
| Fresenius Kabi USA, LLC | $48.69 | 2023 | Idacio |
| Genentech USA, INC. | $44.70 | 2021 | |
| Celgene Corporation | $37.68 | 2023 | Sotyktu |
| Ani Pharmaceuticals, INC. | $22.81 | 2025 | Veregen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw A Brunner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.